Last reviewed · How we verify
GB001
At a glance
| Generic name | GB001 |
|---|---|
| Sponsor | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers (PHASE2)
- Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects (PHASE1)
- Heat Therapy for Peripheral Arterial Disease (HEATPAD) (NA)
- GB001 in Adult Subjects With Moderate to Severe Asthma (PHASE2)
- GB001 in Adult Participants With Chronic Rhinosinusitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB001 CI brief — competitive landscape report
- GB001 updates RSS · CI watch RSS
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. portfolio CI